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Carotid stenting has been proposed as an alternative to reoperative carotid endarterectomy (rCEA) for recurrent carotid
stenosis. The purpose of this study is to prove the safety, effectiveness and durability of reoperation in long term follow
up of 18 years in a community hospital setting. From March 1988 to April 2005 80 patients, 46 men and 34 women
(mean age: 64.1 years) underwent a total of 83 operations. Symptomatic recurrent stenosis (>70%) was the indication
in 32, asymptomatic high-grade stenosis (>80%) in 49, intimal flap in one and fibromuscular dysplasia (F.M.D), in one.
The initial operation was carotid endarterectomy with primary closure in 60 and prosthetic patch in 23. The mean
recurrences were at 23.3 months in 33 with myointimal hyperplasia, 105.4 months in 29 with recurrent atherosclerosis,
61.4 months in 19 with both hyperplasia and atherosclerosis, 2 months in one with intimal flap and 8 months in one
with F.M.D bands. Reoperation utilized primary closure (3), vein patch (14), prosthetic patch (55), Gore-Tex interposition
grafts (7), vein interposition grafts (3) and intraoperative dilation (1).
No perioperative strokes or deaths occurred. One patient died from cardiac complications following combined rCEA and
coronary artery bypass grafting. Operative morbidity consisted of reversible nerve injury (5), irreversible recurrent laryn-
geal nerve injury (1) and hematoma requiring evacuation (3). During follow up (3e153 months; mean: 50.9) carotid oc-
clusion resulted in mild ipsilateral stroke in one patient, and one non-hemispheric stroke. There were 26 late deaths due to
all causes, one due to CVA. Eight patients required reoperation (mean 53.4 months). Seven of these were hypertensive.
Kaplan-Meier analysis of long-term follow up shows relatively high stroke free rates; at 153 months (12.75 years) the
hemispheric stroke free rate was 98.67% and the all-stroke free rate was 95.85%. The survival estimate following redo sur-
gery was 69.97% at 5 years and 40.23% at 10 years. We found that individuals on statin therapy (p-value¼ 0.0042), and
those on combination of statin and aspirin (p-value¼ 0.0320), had significantly increased interval between primary and
secondary operation. Increased age was correlated to a decreased time to redo surgery (p-value¼<0.0001).
We conclude that reoperation for recurrent carotid stenosis using standard vascular techniques is safe, effective, durable
and cost effective. It should continue to be the mainstay of treatment when secondary intervention is required. Statins have
a salutary effect on durability of the procedure and should be used when indicated.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Carotid endarterectomy is the gold standard for treat-
ment of symptomatic and asymptomatic flow limiting
carotid artery disease as compared to medical treat-
ment for prevention of stroke.1e3 This is supported
by the results of the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) and Asymp-
tomatic Carotid Atherosclerosis Study (ACAS) clinical
trials.1,2 CEA is not only durable, but has been shown
to have low operative risks. The perioperative risks
are clearly defined.4,5 However the increase in CEA’s
performed has also resulted in an increase in the
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sis as reflected in the approximate 2% to 5% incidence
of reoperation.6e10
It has been suggested that local anatomic complica-
tions such as nerve damage occur frequently in patients
undergoing operation for restenosis, and with the
added difficulty of redissection in the prior operative
field, new treatment modalities such as carotid artery
stenting have been proposed as safer alternatives to
rCEA.11,12 As a result,most carotid artery stenting trials
classify rCEA among the high-risk inclusion criteria. In
the NASCET trial the recurrent carotid artery stenosis
was one of the exclusion criteria. This has also resulted
in categorization of recurrent stenosis in the high risk
group by the proponents of carotid stenting. In the trial,
Stenting andAngioplasty with protection in patients at
High Risk for Endarterctomy (SAPPHIRE) it has been
documented that carotid stenting is not inferior toar Surgery. Published by Elsevier Ltd. All rights reserved.
562 S. Jain et al.CEA.13 The results of this trial continue to be debated
because of the study design.
In 1998 we had published our 10 year experience in
performing CEA for recurrent stenosis.14 In the current
study our purpose is to prove the safety, effectiveness
and durability of rCEA as seen in long term follow
up of 18 years. This is especially pertinent as the pa-
tients continue to present with recurrent stenosis
to various specialists and in the days of evidence
based medicine we should be able to advise patients
appropriately from both a clinical and an economic
perspective.
Methods
Patient selection and data collection
In this retrospective study a review was performed of
all patients who underwent an operation for recurrent
carotid stenosis between March 1988 and May 2005 by
our group of three board certified vascular surgeons in
a community hospital setting. The original operations
were not always performed by the group. Patient de-
mographics were obtained from patient charts and in-
dications and technique for the original operationwere
identified when possible in a retrospective manner. All
of the original operative notes were not available. The
temporal relationship from primary CEA and type of
reconstruction (type of patch or primary closure) and
the technique in treating the recurrent carotid stenosis
was documented. Patients’ clinical and laboratory
data, operative details, post operative carotid noninva-
sive studies and clinical course for those undergoing
rCEA were obtained. Clinical criteria determination
made at time of rCEA included: hypertension, diabetes
mellitus, coronary artery disease, history of cigarette
smoking, high cholesterol as determined by lab values,
family history of coronary disease, and the use of aspi-
rin or statins. Carotid stenosis symptoms including
hemispheric and non-hemispheric TIA and amaurosis
fugax were documented. In asymptomatic patients,
a second operation was performed in patients who
displayed greater than 80% restenosis, intimal flap
causing hemodynamically significant stenosis or fibro-
muscular dysplasia. No patient was rejected because of
underlying co-morbidities.
All operations were carried out under general anes-
thesia. A shunt was routinely used unless it could not
be placed for technical reasons. Various techniques
were used for reconstruction. When intimal hyper-
plasia is identified, an attempt is made to perform an
intimectomy, however it is not always possible to do
a complete removal of thickened intima. A patch isEur J Vasc Endovasc Surg Vol 34, November 2007routinely used in either circumstance. If indicated a by-
pass is performed. Hospital and patient office records
were screened for any adverse events during the hospi-
talization that was associated with surgical proce-
dures. Particular weight was placed on postoperative
cardiovascular and neurologic status as documented
on record. A perioperative stroke was defined as a cen-
tral neurologic deficit ipsilateral to the operative side.
Other complications examined included hematoma re-
quiring drainage and reversible or irreversible laryn-
geal nerve injury which was determined clinically.
Follow up included clinical exam and duplex inter-
rogation of the operative site at 6 weeks, 6, and 12
months after discharge, and annually thereafter. The
primary end point was stroke. Secondary end points
included death or lost to follow up. Review of cause
of death was performed to determine if it was due
to carotid disease. An attempt was made to call the
families when the patient was lost to follow up or
died in another facility. Patients who were lost to fol-
low up usually moved out of state to warmer climates
or could not return for follow up because of socioeco-
nomic reasons.
Recurrent (tertiary) stenosis: Follow up continued
anywhere from 3 to 153 months (mean 50.9 months)
unless evidence of another restenosis developed as
was the case after eight reoperations. These tertiary
surgeries took place from 5 to 147 months after the
second operation for restenosis with a mean of 53.4
and a median of 46.5 months. The time between the
primary and tertiary operations ranged from 12 to
153 months with a mean of 88.3 and a median of 84
months. The original criteria for reoperation were
used. Seven of the patients were asymptomatic and
had >80% stenosis, one patient had TIA and >70%
stenosis.
Statistical analysis: Data were tabulated and Kaplan-
Meier analysis was performed on survival and stroke
free interval. A multivariate analysis was carried out
to see if any of the risk factors had a significant impact
on long term result. T-tests were performed when
appropriate.
Results
Between 1988 and 2005, 80 patients, (mean age: 64.1
years) underwent a total of 83 rCEAs. Of these pa-
tients, 32 underwent the second operation due to
symptomatic recurrent stenosis (>70%), 49 presented
with asymptomatic high-grade stenosis (>80%), one
with an intimal flap and one with F.M.D. In these
asymptomatic patients, 22 had intimal hyperplasia,
16 had recurrent atherosclerosis and 11 had a com-
bination of intimal hyperplasia and recurrent
563Operative Intervention for Carotid Restenosisatherosclerosis. Patients were followed by serial ultra-
sound and operated on when the stenosis became
greater than 80%, even if the patient was asymptom-
atic. Primary closure was used in 60 of the primary
cases, and prosthetic patch in 23 (Table 1). Of the 60
procedures in which the original operation was pri-
mary closure, findings at the time of second operation
included; 24 intimal hyperplasia 21 atherosclerosis, 14
combined atherosclerosis and intimal hyperplasia and
1 intimal flap. Of the 23 original prosthetic patch pro-
cedures, findings at the time of second operation
were: 9 intimal hyperplasia, 9 atherosclerosis, 4 ath-
erosclerosis and intimal hyperplasia and one fibro-
muscular dysplasia.
There were no patients in the symptomatic category
who had less than 70% stenosis. The average time from
primary CEA to recurrence was 23.3 months in the 33
patients who presented with myointimal hyperplasia,
105.4 months in the 29 with recurrent atherosclerosis,
61.4 months in the 19 presenting with both problems
as determined intraoperatively and on histology, two
months in the patient with an intimal flap, and 8
months for the patient with symptomatic fibromuscu-
lar dysplasia beyond the site of the original carotid
endarterectomy. The patient had magnetic resonance
angiography before the initial endarterectomy and
fibromuscular dysplasia was not identified. The aver-
age time from primary CEA to recurrence in symp-
tomatic patients was 64.9 months with a median of
Table 1. Demographics and risk factors
N %
Men 46 57.5
Women 34 42.5
Age at first operation 64.1 1.0
Tobacco use (any history) 52 65
Hypertension 65 81.25
Diabetes 19 23.75
High cholesterol 54 67.5
Family History of stroke 30 37.5
Coronary artery disease 39 48.75
Statin therapy 46 57.5
Aspirin therapy 72 90
Reasons for redo-operation
Symptomatic
AF 3 3.61
TIA e HEMI 22 26.50
TIA e NON HEMI 7 8.43
Asymptomatic 49 59.03
Intimal Flap 1 1.20
FMD 1 1.20
Initial Operation
Primary closure 60
Prosthetic 23
FMD, Fibromuscular dysplasia; AF, Amarousis fugax; TIA, Tran-
sient ischemic attack; Hemi, Hemispheric; Non-Hemi, Non
Hemispheric.56.5. In asymptomatic patients the average time
between surgeries was 56.1 months with a median of
49.5. Recurrent stenosis was identified preoperatively
by ultrasonic examination in all patients. A compari-
son of the mean time to restenosis between symptom-
atic and asymptomatic patients was analyzed using
a t-test and was found not to be statistically significant.
Our lab uses a peak systolic velocity of 250 cm/sec,
a peak diastolic velocity of 100 cm/sec and a systolic
velocity ratio of 3.7 to diagnose a stenosis of greater
than 80%. MRA or arteriography was performed
rarely to confirm the ultrasonic diagnosis.
All patients received general anesthesia. Reopera-
tion utilized primary closures in three, fourteen vein
patches, 55 prosthetic patches, seven Gore-Tex inter-
position grafts, three vein interposition grafts and
one intraoperative dilation for the patient with fibro-
muscular dysplasia (Table 2).
No perioperative strokes occurred (Table 3). There
was one perioperative death unrelated to the rCEA
in a patient who underwent combined coronary ar-
tery bypass grafting with rCEA and died from cardiac
complications. Operative morbidity consisted of re-
versible recurrent laryngeal nerve injury in five, irre-
versible recurrent laryngeal nerve injury in one and
hematoma requiring evacuation in three. During fol-
low up, carotid occlusion resulted in mild ipsilateral
stroke in one patient. This patient was operated on
for asymptomatic stenosis which was caused by
a long segment of intimal hyperplasia. The stroke oc-
curred three months after the redo operation. One pa-
tient had non-hemispheric stroke due to small vessel
disease. There were 26 late deaths due to all causes
including one due to cerebrovascular accident as
Table 2. Surgical characteristics
N %
General
Total Redo Procedures 83 100
Average time from first
CEA (2 to 218 months)
59.7 5.9 e
Contralateral CEA 34 41
Bilateral Redo CEA 3 3.6
Redo-Operation Procedure
Primary Closure 3 3.6
Intraoperative dilation 1 1.2
Interposition Graft
Gortex 7 8.4
Vein 3 3.6
Total Patches
Dacron patch 4 3.6
Hemashield patch 22 26.5
Acuseal patch 22 26.5
Goretex patch 7 8.4
Vein patch 14 16.9
CEA, Carotid endarterectomy.Eur J Vasc Endovasc Surg Vol 34, November 2007
564 S. Jain et al.determined by hospital records. The cause of death
could not always be determined. Only eight opera-
tions were performed for tertiary restenosis at 5, 10,
49, 58, 82, 32, 44 and 147 months (mean: 53.4 months).
Seven of these patients were hypertensive. Seven op-
erations were carried out in asymptomatic patients
and one patient had a TIA.
Follow up ranged from 3 to 153 months (mean 50.9
months, median 42 months). Kaplan-Meier analysis of
long-term follow up shows relatively high stroke free
rate. At 153 months (12.75 years) the hemispheric
Table 3. Operative complications and follow up
N %
Complication
Perioperative CVA 0 0
Perioperative death 1 1.2
Hematoma requiring drainage 3 3.6
Reversible nerve injury 5 6
Irreversible recurrent
laryngeal nerve injury
1 1.2
Follow-up 3 to 153 months (mean: 50.9 months)
Recurrent stenosis
requiring tertiary operation
8 9.6
Average time between second
and third operation
53.4 16 months
Stroke on operative side 1 1.3
Stroke, nonhemispheric 1 1.3
Death due to CVA (nonhemispheric) 1 1.3
Death due to other causes 25 31.3
Lost to follow-up (mean: 21.4 months) 18 22.5
Recurrence of symptoms after redo (TIA)
resulting in tertiary operation
1
CVA, Cerebrovascular accident.Eur J Vasc Endovasc Surg Vol 34, November 2007stroke free rate was 98.67% (Fig. 1, Table 4) and the
all-stroke free rate was 95.85% (Fig. 2, Table 5). The
survival estimate following redo operation was
69.97% at 5 years and 40.23% at 10 years (Fig. 3,
Table 6). We found that individuals on statin therapy
(mean: 67.38 months; p-value¼ 0.0042), and those on
a combination of statin and aspirin (mean: 62.32
months; p-value¼ 0.0320), had significantly increased
time to redo operation. Those on just aspirin (mean:
52.12 months) and those on neither statin nor aspirin
(mean: 25 months) (Table 7) are likely to have earlier
recurrence. Using a Pearson product correlation, an
increased age was correlated to a decreased time to
redo operation ( p-value¼<0.0001). We did not find
a significant correlation between risk factors (single
and paired) or gender and cause for restenosis (inti-
mal hyperplasia, atherosclerotic plaque or both).
Risk factors included hypertension, family history, di-
abetes mellitus, coronary artery disease, tobacco use
and hypercholesterolemia. There also did not seem
to be a correlation between risk factors or gender
and the need for third operation.
Discussion
Carotid Endarterectomy has been shown to be safe
and effective in various randomized trials both in the
United States in the NASCET and ACAS trials,1,2 and
in Europe in the ECST and ACST trials.34,35 However,
the role of surgery for recurrent carotid artery stenosis
has become controversial in the recent past due to the
advent of endovascular techniques. Various authors0.00
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Fig. 1. Hemispheric Stroke Free Survival using Kaplan-Meier curve from the time of reoperation. Numbers in graph repre-
sent patients being followed at 12 month intervals.
565Operative Intervention for Carotid Restenosishave reported stroke/mortality rates with surgery
to be less than 5%. This is within the guidelines recom-
mended by NASCET and the Ad Hoc Committees of
the American Heart Association on Carotid Surgery
Standards.14e16 In guidelines presented by American
Heart Association, the stroke/death rate of <6% for
symptomatic patients, and <3% for asymptomatic pa-
tients is acceptable and for rCEA the acceptable rate is
<10%.17 Our results are well within these guidelines.
We believe that the low rate of major adverse outcomes
in this study, which has also been echoed by other reo-
perative series with stroke/death rates noted between
0% and 7%, make the redo operation very safe18,19
Many studies, ours included, indicate the operative
risk of rCEA is similar to that of first-time opera-
tion.6e8 The operation is durable as seen by our long
term clinical and ultrasonic follow up of the carotid
arteries.
Our group’s approach has been to recommend
reoperation in otherwise good-risk patients with
asymptomatic high-grade stenosis greater than 80%
or for symptomatic stenosis greater than 70%. The
choice of operation depends on several factors and
Table 4. Hemispheric stroke free survival rate
Total Failed Censored Percent Censored
80 1 79 98.75
Summary of the Number of Censored and Uncensored Values. Only
one survival time has failed and 79 were censored. Failure were ob-
served at 3 months (S(t)¼ 0.9867; Std. Error¼ 0.0132).the procedures include endarterectomy, patch angio-
plasty and resection/grafting. The procedure used
depends on the operative findings. If the artery has
a thin web of intimal hyperplasia, this can often be
peeled off and the artery is then closed with a patch.
Recurrent atherosclerosis can be removed along a
plane as in the first operation. Long segment smooth
stenosis sometimes only requires a patch. In patients
with severely thickened arteries, or those without an
easily established plane of dissection, resection and
grafting is the procedure of choice.14 We follow a sim-
ilar practice.
The reason to carry out the reoperation is to pre-
vent strokes. In our study, during follow-up, carotid
occlusion resulted in a mild ipsilateral stroke in one
patient which compares favorably with long-term
results shown in the NASCET report. One patient
had a non-hemispheric stroke which is within the
13% 5-year ‘‘risk of any stroke or perioperative death’’
reported in the ACAS study.14 Of 26 late deaths, one
was due to CVA as determined by hospital records.
Our results show a 98.7% hemispheric stroke free
survival and 95.85% all stroke free survival. These
results are similar to the results published by Stoner
et al. who reported a stroke free rate of 96% during
a mean follow up of 4.4 years.20 Since we did not
know the cause of death for all the patients, it is pos-
sible that some patients may have died as a result of
stroke.
Another concern of reoperative carotid operation is
the possibility of injuring an adjacent structure (e.g.0.00
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Fig. 2. All Stroke Free Survival using Kaplan-Meier curve from the time of reoperation. Numbers in graph represent patients
being followed at 12 month intervals.Eur J Vasc Endovasc Surg Vol 34, November 2007
566 S. Jain et al.cranial nerves or internal jugular vein). It seems to be
the natural tendency for these structures to become ad-
herent to the planes of previous dissection.21 However,
the use of bluemonofilament suturemakes reoperation
fairly straightforward if patience and due diligence are
exercised. The color of the suture makes it easy to go
down to the previous suture line. The dissection is
also often surprisingly easy the further in time one
gets after the original operation.14 In our study there
were only six nerve injuries which were clinically ap-
parent, five of which were reversible. One patient had
persistent vocal cord paralysis. Cranial nerve injury is
recorded in the 0% to 7% range in several publications
for reoperative carotid operation.22e24 These arewithin
ranges suggested for first-time carotid surgery.25 There
was no attemptmade to do routine independent neuro-
gical or laryngoscope evaluation if not clinically war-
ranted. Occasionally, reoperation for neck hematoma
is required.Wedonot routinely take patients off aspirin
prior to the operation. Heparin is always reversed. Oc-
casionally lowmolecular weight Dextran is used intra-
operatively and postoperatively but there was no
Table 5. All stroke free survival rate
Total Failed Censored Percent Censored
80 2 78 97.50
Summary of the Number of Censored and Uncensored Values. Only
two survival time has failed and 78 were censored. Failure were
observed at 3 months (S(t)¼ 0.9867; Std. Error¼ 0.0132) and 51
months (S(t)¼ 0.9585; Std. Error¼ 0.0306).Eur J Vasc Endovasc Surg Vol 34, November 2007correlation found between the use of Dextran and post-
operative bleeding. Currently patients are taken off
Clopidogrel for two weeks prior to an operation. In
our study neck hematoma requiring operation rate
was 4% (three cases) which is consistent with previ-
ously published and acceptable rates as defined by ran-
domized trials.1,17,20 These results demonstrate that
meticulous surgical technique can yield excellent re-
sults, despite the presence of a reoperative field.20
Studies have shown the salutary effect of HMG-Co
A reductase inhibitors on the progression of vascular
disease. We had 46 patients on statins after the pri-
mary operation. We found a significant delay in de-
veloping recurrent stenosis requiring operation
when the patients were on statins or statins and
aspirin. We would recommend the use of statins
post carotid endarterectomy as also reported by
LaMuraglia et al.26
The effect of age on CEA needs further attention.
We noticed that increased age at the time of carotid
endarterctomy has a negative impact on developing
restenosis. In a study of nonagenarians published by
our group we showed that vascular operation can be
safely carried out when appropriate measures are
taken.27 We continue to offer the operation to patients
at any age if they are functional.
We have low recurrence rates, as is also seen in
other reports.20,28,29 Long term follow-up in our pa-
tients displays good results with only eight incidences
of tertiary stenosis requiring operation. The recur-
rence rate after redo endarterectomy of ten percent5167 44 37 29 24 20 15 7 6 5 3 080
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Fig. 3. Survival using Kaplan-Meier curve from the time of reoperation. Numbers in graph represent patients being fol-
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567Operative Intervention for Carotid Restenosisin this series may be considered by some to be high
however this is one of the very few reports looking
at a long term follow up in this population. Modifying
their risk factors may help to decrease recurrent steno-
sis. Seven of these patients had hypertension. This
was not found to be statistically significant. This
may be because of sample size. Other authors have
shown a higher incidence of hypertension in patients
presenting with recurrent stenosis.30,31 This finding
should promote physicians to better control hyperten-
sion in this group of patients. We did not find any
other risk factor to correlate with recurrent stenosis
as reported by other authors. Once again it may be
due to sample size. A meta analysis of various studies
may show a better relationship between various risk
factors and recurrent stenosis.
Outcomes with carotid stenting performed as the
reoperative intervention have shown a comparable
incidence of complications including TIA, stroke, re-
stenosis and death in the 30 day period following
the procedure.32 In the data being presented we
were able to carry out the operation without proce-
dure related stroke or death. There was only one
perioperative death due to cardiac complications
following combined rCEA and coronary artery bypass
grafting. The results of combined operation tend to be
different as compared to CEA alone. However, for the
sake of completion we have included this patient in
this series. Patients having carotid stenting for recur-
rent carotid stenosis have been shown to have higher
stroke rate, restenosis rate, and lower stroke free sur-
vival rate32,33 as compared to our data.
We recognize there are inherent weaknesses to our
study as with any retrospective review or report.
Table 6. Long term survival
Total Failed Censored Percent Censored
80 26 54 67.50
Summary of the Number of Censored and Uncensored Values.
Table 7. Multivariate analysis of risk factors associated with
progression to recurrent carotid artery stenosis
Variable Hazard Ratio 95% CI p-value
Hypertension 0.7517 [0.4972, 9.0451] 0.3097
Family History 1.715 [0.7789, 3.7720] 0.1806
Diabetes Mellitus 1.021 [0.3801, 2.7420] 0.9672
Coronary artery disease 1.845 [0.8217, 4.1445] 0.1377
Smoking 0.543 [0.2417, 1.2184] 0.1385
Hypercholesterolemia 0.435 [0.1979, 0.9559] 0.0382
Gender 1.447 [0.6565, 3.1889] 0.3595
Aspirin 1.121 [0.3241, 3.8758] 0.8570
Statin 0.302 [0.1330, 0.6850] 0.0042*
Aspirin and statin 0.396 [0.1698, 0.9233] 0.0320*
* p < 0.05.Occasionally the follow up is incomplete because
patients died at another facility or did not return for
follow up visits. The primary operation was not
always performed by our group resulting in variable
surgical techniques. Since the incidence of recurrent
stenosis requiring intervention is low, it is difficult to
have a prospective study for this group of patients.
Conclusions
Reoperation for recurrent carotid stenosis, using stan-
dard vascular techniques, is safe, effective and dura-
ble. In patients with symptomatic 70% stenosis and
asymptomatic 80% stenosis the operation can be car-
ried out with low risk and long stroke free survival.
Statins should be diligently used when indicated.
The operation can be safely carried out in a community
hospital setting when performed by board certified
vascular surgeons. Carotid endarterctomy should con-
tinue to be the mainstay of treatment when secondary
intervention is required.
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